Barrington Research Lowers DENTSPLY SIRONA (XRAY) to Market Perform

DENTSPLY SIRONA (NASDAQ:XRAY) was downgraded by equities research analysts at Barrington Research from an “outperform” rating to a “market perform” rating in a research note issued on Thursday, Marketbeat Ratings reports.

The analysts wrote, “We are cutting our investment rating to MARKET PERFORM in response to XRAY’s weak financial guidance for the remainder of FY/18 and the massive uncertainty we still see surrounding this business beyond this year. This update marks a new low in DENTSPLY SIRONA’s disappointing 2 ½ year history as a combined publicly-traded company.””

Other research analysts also recently issued research reports about the stock. Deutsche Bank decreased their price target on shares of DENTSPLY SIRONA to $55.00 and set a “buy” rating for the company in a research note on Wednesday, May 16th. Zacks Investment Research downgraded shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research note on Friday, May 11th. Stifel Nicolaus reiterated a “buy” rating and issued a $57.00 price target (down previously from $67.00) on shares of DENTSPLY SIRONA in a research note on Tuesday, May 8th. Robert W. Baird decreased their price target on shares of DENTSPLY SIRONA to $71.00 and set an “outperform” rating for the company in a research note on Tuesday, May 8th. Finally, Jefferies Financial Group decreased their price target on shares of DENTSPLY SIRONA from $58.00 to $46.00 and set a “buy” rating for the company in a research note on Wednesday. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $52.75.

Shares of DENTSPLY SIRONA stock opened at $40.39 on Thursday. DENTSPLY SIRONA has a 52-week low of $38.83 and a 52-week high of $68.98. The company has a quick ratio of 1.46, a current ratio of 2.23 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $11.02 billion, a P/E ratio of 15.18, a PEG ratio of 2.51 and a beta of 1.27.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Tuesday, August 7th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.01. DENTSPLY SIRONA had a negative net margin of 38.32% and a positive return on equity of 8.63%. The company had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter in the previous year, the firm earned $0.65 earnings per share. equities research analysts anticipate that DENTSPLY SIRONA will post 2.59 EPS for the current fiscal year.

In other news, Director Michael C. Alfano sold 1,404 shares of the business’s stock in a transaction that occurred on Wednesday, May 30th. The shares were sold at an average price of $45.83, for a total transaction of $64,345.32. Following the completion of the sale, the director now owns 13,458 shares in the company, valued at approximately $616,780.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael J. Coleman sold 6,038 shares of the business’s stock in a transaction that occurred on Friday, June 1st. The stock was sold at an average price of $43.97, for a total transaction of $265,490.86. Following the sale, the director now owns 26,960 shares of the company’s stock, valued at approximately $1,185,431.20. The disclosure for this sale can be found here. 1.93% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of XRAY. Piedmont Investment Advisors LLC purchased a new stake in DENTSPLY SIRONA in the 2nd quarter valued at $117,000. Jane Street Group LLC purchased a new stake in DENTSPLY SIRONA in the 4th quarter valued at $313,000. IBM Retirement Fund raised its position in DENTSPLY SIRONA by 49.1% in the 1st quarter. IBM Retirement Fund now owns 4,955 shares of the medical instruments supplier’s stock valued at $249,000 after purchasing an additional 1,631 shares during the last quarter. NuWave Investment Management LLC raised its position in DENTSPLY SIRONA by 184.6% in the 1st quarter. NuWave Investment Management LLC now owns 5,237 shares of the medical instruments supplier’s stock valued at $263,000 after purchasing an additional 3,397 shares during the last quarter. Finally, Northwest Investment Counselors LLC raised its position in DENTSPLY SIRONA by 21.0% in the 2nd quarter. Northwest Investment Counselors LLC now owns 7,582 shares of the medical instruments supplier’s stock valued at $332,000 after purchasing an additional 1,318 shares during the last quarter. Institutional investors and hedge funds own 94.10% of the company’s stock.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

See Also: Trading Strategy Examples and Plans

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply